newsfilter
← Latest News
GlobeNewswire·

Cellectis announces the drawdown of the third tranche of €5 million under the credit facility agreement entered with the European Investment Bank (EIB)

NEW YORK, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Cellectis (NASDAQ:CLLS) (the "Company"), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene